Exposure to tablet powder (either airborne or by dermal contact) generated during the breaking or crushing of olanzapine tablets has the potential risks for contact dermatitis following repeated exposure.1

Symptoms have included rash with redness, swelling, and scaling of the affected skin areas. Positive reactions have been verified by patch testing with olanzapine (0.1%). Based on the clinical dose, olanzapine is highly potent.1

Likewise, olanzapine may be irritating to the eyes based on animal studies. Attention and care should be exercised not to inadvertently transfer material from the hands to the eye.2

Additional safety information about olanzapine can be found in the full prescribing information and the Material and Safety Data Sheet, available upon request from Eli Lilly and Company.